Company Snapshot

Veeda Clinical Research is one of India’s leading independent CROs, distinguished by robust regulatory credentials, expanding global footprint through acquisitions/JVs, and a strong revenue base, now gearing up for a major IPO to fund further growth.

Veeda is a full-service Clinical Research Organization (CRO) headquartered in Ahmedabad, offering end-to-end services across the drug development lifecycle:

• Preclinical and non-clinical studies
• Healthy volunteer (HVS), bioavailability, and bioequivalence trials
• Early- to late-phase (Phase I–IV) clinical trials
• Bioanalytical testing, including large-molecule assays

Global Reach & Capabilities

• Regulatory Compliance: Passed 119 global inspections (including US FDA, MHRA, ANVISA, WHO).
• Facilities: Operates seven facilities in India, located in Ahmedabad, Mehsana, and Bangalore.

Growth & Strategic Moves

• <>span2024: Acquired European oncology-focused CRO Heads, enhancing global trial capabilities.
• Acquired majority stake in Bengaluru-based preclinical CRO Bioneeds.
• 2021: Joint venture with Somru BioScience to launch Ingenuity BioSciences in Ahmedabad.

Industry Outlook

Market Size & Growth

• 1. Clinical CRO Market:
  • USD 2,501.7 million in 2024 (~₹20,850 crore)
  • Expected to reach USD 4,410 million (~₹36,800 crore) by 2030 (CAGR 9.9%)
• 2. Overall CRO Market (incl. preclinical):
  • USD 0.73 billion in 2024 (~₹6,070 crore)
  • Expected to grow to USD 1.32 billion (~₹10,980 crore) by 2032 (CAGR ~7.2%)

Key Growth Drivers

• Cost competitiveness: Trials in India cost 30–50% less than in the West.
• Large patient population: Enables faster enrollment and diverse studies.
• Regulatory reforms: 2019 rules have halved approval timelines.
• Digital transformation: Use of AI, EDC, remote monitoring, and decentralized trials is increasing efficiency.
• >Therapeutic expansion: Increasing trials in oncology, rare diseases, and biologics.

Summary

• Short-term (1–3 years): Growth in clinical and preclinical services, boosted by tech and regulation.
• Mid-term (3–7 years): Expansion into biologics and CDMO integration.
• Long-term (by 2030): CRO + CDMO revenue potential of ₹1.8 lakh crore (~$25 billion globally).

India's CRO industry is entering a maturing phase, well-positioned to serve global sponsors through a mix of cost leadership, regulatory strength, and tech adoption.

Latest Shareholding Pattern of Veeda Clinical Research Ltd.